Catalyst Pharmaceutical (CPRX -62%) craters after saying earlier that CPP-109, its potential...

|About: Catalyst Pharmaceutical Par... (CPRX)|By:, SA News Editor

Catalyst Pharmaceutical (CPRX -62%) craters after saying earlier that CPP-109, its potential cocaine addiction treatment, failed to meet its primary endpoint versus a placebo in Phase II studies. The data also showed that two key secondary endpoints, a significantly larger increase in cocaine negative urines and a significant decrease in the weekly fraction of use days in medication-treated subjects, also were not met.